HEMOGENYX PHARMACEUTICALS PLC financials
HEMOGENYX PHARMACEUTICALS PLC
2138008L93GYU5GN6179 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | £0 | £0 |
| Administrative expenses | £4.7M | £5.8M |
| Operating profit (EBIT) | £5.4M | £6.5M |
| Finance costs | £271.6K | £316.0K |
| Profit before tax | -£5.6M | -£6.7M |
| Income tax expense | £0 | £0 |
| Profit for the year | -£5.6M | -£6.7M |
| — attributable to owners | -£5.6M | -£6.7M |
| — attributable to NCI | -£6.3K | -£5.8K |
| Total comprehensive income | -£6.0M | -£5.8M |
| Cash flow statement | ||
| Net cash from operating activities | -£4.1M | -£6.1M |
| Net cash from investing activities | -£1.7K | -£31.9K |
| Purchase of PP&E (capex) | £13.3K | £117.3K |
| Net cash from financing activities | £3.1M | £4.4M |
| Repayments of borrowings | £635.0K | £638.8K |
| Net change in cash | -£1.1M | -£1.7M |
| Balance sheet | ||
| Total assets | £4.2M | £6.1M |
| Non-current assets | £3.4M | £3.9M |
| Property, plant & equipment | £759.4K | £966.4K |
| Right-of-use assets | £2.0M | £2.3M |
| Current assets | £839.0K | £2.2M |
| Trade & other receivables | £679.8K | £922.0K |
| Cash & equivalents | £159.3K | £1.2M |
| Total equity | £853.5K | £2.8M |
| — attributable to owners | £897.5K | £2.8M |
| Non-controlling interests | -£44.0K | -£37.7K |
| Non-current liabilities | £2.2M | £2.6M |
| Lease liabilities (non-current) | £2.2M | £2.6M |
| Current liabilities | £1.2M | £741.5K |
| Lease liabilities (current) | £423.7K | £362.5K |
| Trade & other payables | £735.0K | £379.0K |
| Derived metrics | ||
| Free cash flow | -£4.2M | -£6.2M |
| Return on equity | -659.1% | -240.8% |
| Cash conversion ratio | 0.74× | 0.91× |
| Capex coverage | -311.63× | -52.06× |
| Other reported items | ||
| Adjustments For Decrease Increase In Trade Account Receivable | -£2.6K | £4.5K |
| Adjustments For Depreciation Expense | £639.3K | £645.7K |
| Adjustments For Increase Decrease In Trade Account Payable | £346.5K | £28.6K |
| Adjustments For Interest Expense | £271.6K | £316.0K |
| Adjustments For Interest Income | £23.2K | £85.3K |
| Adjustments For Sharebased Payments | £343.9K | £242.8K |
| Comprehensive Income Attributable To Noncontrolling Interests | -£6.3K | -£5.8K |
| Comprehensive Income Attributable To Owners of Parent | -£6.0M | -£5.8M |
| Depreciation Expense | £639.3K | £645.7K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -£24.0K | £403.0K |
| Equity and Liabilities | £4.2M | £6.1M |
| Finance Income | £23.2K | £85.3K |
| Gains Losses On Exchange Differences On Translation Net of Tax | -£358.4K | £903.1K |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | £626.2K | £1.5K |
| Intangible Assets Other Than Goodwill | £477.4K | £470.2K |
| Interest Received Classified As Investing Activities | £23.2K | £85.3K |
| Issue of Equity | £3.9M | £5.3M |
| Issued Capital | £35.0K | £11.8M |
| Liabilities | £3.4M | £3.3M |
| Other Adjustments For Noncash Items | £0 | £81 |
| Other Comprehensive Income | -£358.4K | £903.1K |
| Other Reserves | £1.5M | £1.2M |
| Proceeds From Issuing Other Equity Instruments | £3.7M | £5.1M |
| Reserve of Change In Value of Foreign Currency Basis Spreads | -£436.0K | -£77.5K |
| Retained Earnings | -£29.4M | -£23.8M |
| Share Premium | £21.4M | £19.9M |
Every line item above is a fact tagged in HEMOGENYX PHARMACEUTICALS PLC's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (GBP), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.